Highlights
1 patentProfile claimed by owner
About
Drugs for the Treatment and Prevention of Type 2 Diabetes
Concenter BioPharma develops drugs for treating and preventing type 2 diabetes. The company has developed a family of nonsteroidal chemical complexes made from components approved for clinical use. These new chemical entities constitute a protected platform of drugs with proven efficacy and safety. The members of the platform act as potent anti-inflammatory agents, strong iron-chelating agents, and antibiotic agents. These modes of action jointly assist in treating the causes and/or symptoms of multiple indications. Concenter BioPharma is a subsidiary of Silkim Pharma.
Identity
| Name | Concenter BioPharma |
|---|---|
| Slug | concenter-biopharma-silkim-ltd |
| Type / kind | startup |
| Crunchbase ID | concenter-biopharma-silkim-ltd |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgNn-8scJDA |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ address | Israel |
Web & social
| Website | https://www.concenterbiopharma.com |
|---|---|
| https://www.linkedin.com/company/9496898 | |
| Twitter / X | https://twitter.com/ConcenterBioPha |
| https://www.facebook.com/concenterbiopharma |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Biologicals
Target customers
Healthcare & Life SciencesLife SciencesBiotechnologyPharmaceuticals
Business models
B2B
Tags
biopharmaceuticalbiotechnologyinflammatory-diseasespharma-companiesoral-drugsdrug-discoverydiabetespharmaceuticalsdrug-developmenttype-2-diabetes
Funding
| Total raised | $3.2M |
|---|---|
| Current stage | Series A |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}